Abstracts tagged "pain"

Abstract Number: 1341 • ACR Convergence 2021
Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
Kurt de Vlam¹, Gaia Gallo², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan², David Sandoval², Chen Yen Lin², Danting Zhu², Rebecca Bolce² and Philip Conaghan⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²Eli Lilly and Company, Indianapolis, IN, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area…
Abstract Number: 1902 • ACR Convergence 2021
Gait Alterations Associated with Worsening Knee Pain over 2 Years: A Machine-learning Approach in the MultiCenter Osteoarthritis Study
Kathryn Bacon¹, David Felson², S. Reza Jafarzadeh¹, Vijay Kolachalama¹, Jeff Hausdorff³, Eran Gazit⁴, Neil Segal⁵, Cora Lewis⁶, Michael Nevitt⁷ and Deepak Kumar², ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA, ³Tel Aviv University, Tel Aviv, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵University of Kansas Medical Center, Iowa City, IA, ⁶University of Alabama Birmingham, Birmingham, AL, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: Altered gait is related to structural worsening of knee osteoarthritis (OA). However, it is not known if altered gait is associated with increased risk…
Abstract Number: 0360 • ACR Convergence 2021
Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from the EuropeanMap of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, José Correa-Fernández⁷, Pedro Plazuelo-Ramos⁸ and Denis Poddubnyy⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Pain is a hallmark of axial spondyloarthritis (axSpA) and can significantly deteriorate patients’ health status. This analysis aims to investigate factors associated with pain…
Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Vibeke Strand¹, Anthony Sebba², Savannah Scardo³, Amanda Quebe⁴, Liliana Zaremba-Pechmann⁵ and Peter C Taylor⁶, ¹Stanford University, Portola Valley, CA, ²Division of Rheumatology, University of South Florida, Tampa, FL, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indanapolis, IN, ⁵HaaPACS, Schriesheim, Germany, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…
Abstract Number: 1447 • ACR Convergence 2021
Long-Term Effect of Prescription Non-Steroidal Anti-Inflammatory Drug Regular Use on the Risk of a Knee Replacement
S. Reza Jafarzadeh¹, Tuhina Neogi¹ and David Felson², ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are a primary treatment for osteoarthritis (OA). It is uncertain, however, whether regular use of NSAIDs affects the risk of…
Abstract Number: 1904 • ACR Convergence 2021
“Why Does My Knee Hurt After I Got My Knee Replaced?”: Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement in Patients with Knee Osteoarthritis
Devin Driscoll¹, Priyanka Ballal¹, Na Wang², Laura Frey-Law³, Cora Lewis⁴, Michael Nevitt⁵ and Tuhina Neogi¹, ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA, ³University of Iowa, Iowa City, IA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵University of California San Francisco, Orinda, CA
Background/Purpose: Some people with knee osteoarthritis (OA) have persistent pain post-knee replacement, but why this occurs is not fully understood. One possibility is post-surgical neuropathy.…
Abstract Number: 0379 • ACR Convergence 2021
Pain Sensitivity in Axial Spondyloarthritis – Comparisons Between Patients and Controls, Women and Men, and Between Different Pain Groups
Elisabet Lindqvist¹, Tor Olofsson², Stefan Bergman³, Ann Bremander⁴, Mats Geijer⁵, Lars Erik Kristensen⁶, Jack Kvistgaard Olsen⁶, Jonas Sagard⁷, Johan Karlsson Wallman⁸ and Elisabeth Mogard¹, ¹Department of Rheumatology, Skane University Hospital, Lund, Sweden, ²Lund University and Skane University Hospital, Lund, Sweden, ³Spenshult Research and Development Centre, Halmstad, Sweden, ⁴Spenshult research and development centre, Vilsharad, Sweden, ⁵University of Gothenburg, Sahlgrenska Academy, Institute of Clinical Sciences, Department of Radiology, Göteborg, Sweden, ⁶Parker Institute, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Department of Rheumatology, Copenhagen, Denmark, ⁷Skåne University Hospital, Lund, Sweden, ⁸Lund University and Skane University Hospital, Hjarup, Sweden
Background/Purpose: Chronic widespread pain (CWP) is common in axial spondyloarthritis (axSpA). For ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) patients, no differences were found in…
Abstract Number: 0749 • ACR Convergence 2021
Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial
Xenofon Baraliakos¹, Louis Bessette², Carlo Salvarani³, Naijun Chen⁴, Ralph Lippe⁵, Jayeshkumar Patel⁴, In-Ho Song⁴, Patrick Zueger⁶ and Philippe Goupille⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Laval University, Québec City, QC, Canada, ³Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Universita di Moderna e Reggio Emilia, Reggio Emilia, Italy, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁶AbbVie Inc., Mettawa, IL, ⁷University hospital of Tours, Rheumatology department, Tours, France
Background/Purpose: Back pain is the hallmark disease feature for patients (pts) with AS. However, the relationship between back pain and other patient-centric outcomes and disease…
Abstract Number: 1456 • ACR Convergence 2021
Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis – A Randomized, Double-blind Placebo-controlled Trial
Jonathan Vela¹, Salome Kristensen², Lene Dreyer², Kristian Kjær Petersen³ and Lars Arendt Nielsen³, ¹Dept. of Rheumatology Aalborg Denmark, Aalborg, Denmark, ²Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ³Aalborg University, Aalborg, Denmark
Background/Purpose: Medical cannabis is increasing in popularity yet the recent International Association for the Study of Pain presidential task force on cannabis and cannabinoid analgesia…
Abstract Number: 1912 • ACR Convergence 2021
Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis
Peter Mandl¹, Paul Studenic², Farideh Alasti¹, Rainer Kaltenberger³, Andreas Kerschbaumer¹, Thomas Krennert³, Josef Smolen¹ and Daniel Aletaha⁴, ¹Medical University of Vienna, Vienna, Austria, ²Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ³Central Institute for Meteorology and Geodynamics, Vienna, Austria, ⁴Medical University Vienna, Vienna, Austria
Background/Purpose: The notion that weather conditions may influence the symptoms and course of rheumatic and musculoskeletal diseases goes back to ancient times. We aimed to…
Abstract Number: 0474 • ACR Convergence 2021
Correlation of Fibromyalgia Survey Questionnaire and Quantitative Sensory Testing Among Patients with Active Rheumatoid Arthritis
Meriah Moore¹, Beth Wallace², Jing Song³, Lutfiyya Muhammad⁴, Andrew Heisler⁵, Daniel Clauw¹, Marcy Bolster⁶, Wendy Marder¹, Tuhina Neogi⁷, Alyssa Wohlfahrt⁸, Dorothy Dunlop⁹ and Yvonne Lee⁹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Northwestern University, Worthington, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Bronson Rheumatology Specialists, Kalamazoo, MI, ⁶Massachusetts General Hospital, Boston, MA, ⁷Boston University School of Medicine, Boston, MA, ⁸Tufts University School of Medicine, Boston, MA, ⁹Northwestern University, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) commonly demonstrate disordered pain processing, termed central sensitization (CS). CS is typically measured using quantitative sensory testing (QST), which…
Abstract Number: 0850 • ACR Convergence 2021
Regression Methods for Modeling Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Scores for Early Stage Knee Osteoarthritis
Benjamin Sweigart and Michael LaValley, Boston University School of Public Health, Boston, MA
Background/Purpose: The Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score [range 0-20] is a common outcome measure for clinical trials and observational studies…
Abstract Number: 1471 • ACR Convergence 2021
Oral Administration of Berberine Limits Post-traumatic Osteoarthritis Development and Associated Pain via AMP-activated Protein Kinase (AMPK) in Mice
Jun Li¹, Yun Wang², Di Chen³ and Ru Liu Bryan⁴, ¹Rush University Medical Center, Chicago, IL, ²Valo Health, Lexington, MA, ³Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China (People's Republic), ⁴University of California San Diego and VASDHS, San Diego, CA
Background/Purpose: AMP-activated protein kinase (AMPK), a master regulator of energy balance and metabolism, is implicated to play an important role in cartilage homeostasis. Berberine is…
Abstract Number: 0476 • ACR Convergence 2021
Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis
Marc Martel¹, Lilach Eyal Waldman¹, Romina Sotoodeh¹, Antonio Vigano¹, Yola Moride², Michelle Canac-Marquis³, Rihab Gamaoun³, Maja Kalaba⁴, Pierre Beaulieu², Julie Desroches², Mark A. Ware⁴, Jordi Perez³, Yoram Shir³ and Mary-Ann Fitzcharles¹, ¹McGill University, Montréal, QC, Canada, ²Université de Montréal, Montréal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴Canopy Growth Corporation, Montréal, QC, Canada
Background/Purpose: Fibromyalgia (FM) is characterized by a constellation of symptoms that are often poorly responsive to current treatments, and patients are increasingly turning to medical…
Abstract Number: 0919 • ACR Convergence 2021
Ixekizumab Shows a Distinct Pattern of Pain Improvement Beyond Measurable Inflammation as Assessed by MRI or CRP or BASDAI Questions 5 & 6 in Patients with Ankylosing Spondylitis
Kurt de Vlam¹, Philip Conaghan², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan⁵, Rebecca Bolce⁵, David Sandoval Calderon⁵, So Young Park⁵, Gaia Gallo⁵ and Walter Maksymowych⁶, ¹University Hospitals Leuven, Leuven, Belgium, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada
Background/Purpose: Ixekizumab (IXE) demonstrated rapid efficacy in patients (pts) with AS at week (W) 16 in the absence of elevated inflammation as measured by baseline…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].